Kidney drug combo under microscope: can they keep fluids in check?
NCT ID NCT05884866
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 2 study investigated how the drugs dapagliflozin and balcinrenone, alone or together, affect the body's handling of water and salts in people over 50 with stage 3 chronic kidney disease. Over 28 days, 103 participants took daily pills to measure changes in urine and blood. The goal was to understand the drugs' mechanisms, not to test a cure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapagliflozin and balcinrenone
What this could lead to
If successful, this study could clarify how these drugs work together to manage fluid and salt balance in chronic kidney disease, potentially improving treatment strategies.
What could go wrong
This is a small, early-phase mechanistic study with only 103 participants over 28 days. It is designed to understand how the drugs work, not to prove they are effective treatments. Results may not lead to direct patient benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC RENAL FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Assistance Publique-Hopitaux de Marseille (AP-HM)
Marseille, 13005, France
-
Klinikum Nuernberg
Nuremberg, Bavaria, 90419, Germany